Latest stories on KRYS
Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference
Business Insider56 · neutralgeneral
AuraGxP Expands Executive Leadership and Secures Initial Funding
PR Newswire58 · neutralgeneral
Krystal Biotech initiated with an Outperform at RBC Capital
The Fly61 · neutralanalyst
Krystal Bio granted bullish view at RBC after blockbuster projections
Seeking Alpha73 · bullishanalyst
Krystal Biotech (KRYS) Q2 2026 Earnings Call Transcript
The Motley Fool67 · bullishearnings
Krystal Biotech, Inc. 2026 Q2 - Results - Earnings Call Presentation
Seeking Alpha50 · neutralearnings
Krystal Biotech Earnings Call Signals Profitable Growth
TipRanks67 · bullishearnings
Krystal Biotech outlines $175M-$195M 2026 non-GAAP opex range as VYJUVEK expands overseas pricing talks
Seeking Alpha56 · neutralgeneral
Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Krystal Biotech Shares Slide Despite Earnings Beat as Revenue Misses Forecasts
Yahoo Top42 · neutralearnings
Krystal Biotech Shares Slide Despite Earnings Beat as Revenue Misses Forecasts
InvestorsHub48 · neutralearnings
Krystal Biotech’s Q2 2026: Robust VYJUVEK Momentum, Multiple Late-Stage Readouts Ahead, and Strong Financials
August 3, 2026
MarketChameleon73 · bullishearnings
Why is Krystal Biotech stock sliding today?
Investing.com Markets34 · bearishgeneral
Krystal Biotech GAAP EPS of $1.79 beats by $0.16, revenue of $119.22M misses by $1.82M
Seeking Alpha58 · neutralearnings
Krystal Biotech, Inc. (KRYS) files 8-K
SEC 8-K50 · neutralgeneral
Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results
Business Insider63 · neutralearnings
Krystal Biotech Q2 2026 Earnings Preview
Seeking Alpha55 · neutralearnings
Krystal Biotech: International Expansion And A Vibrant Pipeline
Seeking Alpha78 · bullishanalyst
Krystal Biotech: Profitable, Self-Funding, And Loaded With Optionality
Seeking Alpha67 · bullishanalyst
Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026
StockTitan50 · neutralgeneral
Krystal Biotech, Inc. (KRYS) files 8-K
SEC 8-K50 · neutralgeneral
Index Shuffle: Krystal Biotech Moves Up to S&P MidCap 400 as Berkshire Hathaway Acquisition Alters Key Benchmarks
July 21, 2026
MarketChameleon58 · neutralgeneral
Krystal Biotech joins the S&P MidCap 400 as TMHC and AVNS exit indexes
Seeking Alpha55 · neutralgeneral
Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600
StockTitan50 · neutralgeneral
Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600
PR Newswire50 · neutralgeneral